發送短信 : Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)

  ______     ___                 ___     _____    
 /_   _//   / _ \\      ___     / _ \\  |  __ \\  
   | ||    | / \ ||    /   ||  / //\ \\ | |  \ || 
  _| ||    | \_/ ||   | [] || |  ___  ||| |__/ || 
 /__//      \___//     \__ || |_||  |_|||_____//  
 `--`       `---`       -|_|| `-`   `-`  -----`   
                         `-`